Table 1.

Efficacies of denosumab and romosozumab.

Agent	Duration of treatment (years)	Improvement of BMD	Reference
Denosumab	1	LS 5.0%, TH 2.9%, FN 1.3%	[12]
	2	LS 7.7%, TH 4.0%, FN 3.3%	[80]
	3	LS 9.2%, TH 6.0%	[81]
	3	LS 9.4%, TH 4.8%, FN 4.0%	[82]
	5	LS 13.7%, TH 7.0%, FN 6.1%	[80]
	5	LS 13.1%, TH 6.2%, FN 5.7%	[83]
	6	LS 15.2%, TH 7.5%, FN 6.7%	[82]
	7	LS 16.5%, TH 7.4%, FN 7.1%	[10]
	8	LS 18.4%, TH 8.3%, FN 7.8%	[83]
	10	LS 21.7%, TH 9.2%, FN 9.0%	[10]
Romosozumab	1	LS 11.3%, TH 4.1%, FN 3.7%	[11]
	1	LS 13.7%, TH 6.2%	[85]
	1	LS 13.3%, TH 6.8%, FN 5.2%	[12]

LS – lumbar spine; TH – total hip; FN – femoral neck; BMD – bone mineral density.